US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% SNDK $1,704.16 ▼-0.92% AAPL $332.89 ▼-0.24%
FinancialContent

SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

3.100 +0.120 (+4.03%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
Presentations will feature encore Phase 1 data highlighting the mechanism of action, redosing potential, and early C-peptide response associated with SAB-142, a fully human multi-specific ATG for Stage... 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics (NASDAQ:SABS) Reports Q1 2026 Miss as Clinical Progress and Extended Cash Runway Through 2028 Take Center Stage ↗
Via Chartmill
News headline image
SAB Biotherapeutics Q2 Earnings Call Highlights ↗
SAB Biotherapeutics (NASDAQ:SABS) said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter... 
Via MarketBeat
Topics Earnings
News headline image
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Q1 Earnings Call Highlights ↗
SAB Biotherapeutics (NASDAQ:SABS) said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a wider... 
Via MarketBeat
Topics Earnings
News headline image
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
From Emergent BioSolutions
Via GlobeNewswire
News headline image
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >